Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2260-2267

  Ko, Eunkyung ^a   Kim, Yujin ^a   Kim, Sung Joo ^b   Joh, Jae Won ^b   Song, Sangyong ^b   Park, Cheol Keun ^b   Park, Joobae ^a,b   Kim, Duk Hwan ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CDH1 GENE; CPG ISLAND; DNA METHYLATION; FEMALE; GENE; GENE HYPERMETHYLATION; GSTP1 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA4 GENE; LIVER CELL CARCINOMA; MALE; METHYLATION; P14 GENE; P15 GENE; P16 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SYK GENE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CPG ISLANDS; DNA METHYLATION; FEMALE; GENES, P16; GENES, P53; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 53349156591     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0236     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.
3. Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996;83:1219-22.
4. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10-24.
5. Su PF, Lee TC, Lin PJ, et al. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer 2007;121:1257-64.
6. Li X, Hui AM, Sun L, et al. p16INK4A hypermethylation is associated with hepatitis virus infection, age and gender in hepatocellular carcinoma. Clin Cancer Res 2004;10:7484-9.
7. Anzola M, Cuevas N, Lopex-Martinez M, DePancorbo MM, Burgos JJ. p16INK4A Gene alterations are not a prognostic indicator for survival in patients with hepatocellular carcinoma undergoing curative hepatectomy. J Gastroenterol Hepatol 2004;19:397-405.
8. Pomerantz J, Schreiber-Agus N, Liégeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
9. Mareel M, Boterberg T, Noe V, et al. E-Cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol 1997;173:271-4.
10. Zhong S, Tang MW, Yeo W, Liu C, Dennis Lo YM, Johnson PJ. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinoma. Clin Cancer Res 2002;8:1087-92.
11. Tchou JC, Lin X, Freije D, et al. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinoma. Int J Oncol 2000;16:663-7.
12. Yuan Y, Mendez R, Sahin A, Dai JL. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res 2001;61:5558-61.
13. Goodman PA, Burkhardt N, Juran B, Tibbles HE, Uckun FM. Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia. Oncogene 2003;22:2504-14.
14. Yuan Y, Wang J, Li J, et al. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 2006;12:6687-95.
15. Greence FL, Page FL, Fleming ID. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p. 132.
16. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 2nd English ed. Tokyo: Kanehara; 2003. p. 38.
17. Kim JJ, Chung SW, Kim JH, et al. Promoter methylation of helicase-like transcription factor is associated with the early stage of gastric cancer with family history. Ann Oncol 2006;17:657-62.
18. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
19. Kim DH, Nelson HH, Wiencke JK, et al. p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
20. Lee SN, Park CK, Sung CO, et al. Correlation of mutation and immunohistochemistry of p53 in hepatocellular carcinoma in Korean people. J Korean Med Sci 2002;17:801-5.
21. Koike Y, Shiratori Y, Sato S, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus - an analysis of 236 consecutive patients with a single lesion. Hepatology 2000;32:1216-23.
22. Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 2007;14:2337-47.
23. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-7.
24. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003;163:1371-8.
25. Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, de Pancorbo MM. No association between GSTP1 gene aberrant promoter methylation and prognosis in surgically resected hepatocellular carcinoma patients from the Basque Country (Northern Spain). Liver Int 2003;23:249-54.
26. Wong IHN, Lo YMD, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000;6:3516-21.
27. Matsuda Y, Ichida T, Genda T, Yamagiwa S, Aoyagi Y, Asakura H. Loss of p16 contributes to p27 sequestration by cyclin D1-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003;9:3389-96.
28. Zhu R, Li BZ, Li H, et al. Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis. Pathol Int 2007;57:328-36.
29. Jicai Z, Zongtao Y, Jun L, Haiping L, Jianmin W, Lihua H. Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma. Mol Carcinog 2006;45:530-6.
30. Roncalli M, Bianchi P, Bruni B, et al. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 2002;36:427-32.
31. Kaneto H, Sasaki S, Yamamoto H, et al. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001;48:372-7.
32. Shim YH, Yoon GS, Choi HJ, Chung YH, Yu E. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003;190:213-9.
33. Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA, Varmus HE. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 2005;25:1228-37.
34. Chen YW, Klimstra DS, Mongeau ME, Tatem JL, Boyartchuk V, Lewis BC. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 2007;67:7589-96.
35. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9.
36. Soussi T. p53 Alterations in human cancer: more questions than answers. Oncogene 2007;26:2145-6.